Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 4 Weeks Treatment With BAY 2413555 in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices

NCT05532046 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05532046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05532046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 4 Weeks Treatment With BAY 2413555 in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
September 20, 2022
Completion date
March 31, 2023
Enrollment
22 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure